



Protein Regulatory Mechanisms in Tumorigenesis

Guest Editors:

Dr. Pengda Liu

Lineberger Comprehensive
Cancer Center, The University of
North Carolina at Chapel Hill,
Chapel Hill, NC 27599, USA

Dr. Wenjian Gan

Department of Biochemistry and
Molecular Biology, Medical
University of South Carolina,
Charleston, SC 29425, USA

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editors

Dear Colleagues,

Post-translational modifications play an indispensable role in proper protein quality and functional control. Thus, understanding post-translational protein modifications in normal physiology and pathological conditions not only expands our knowledge on the diversity of the proteome, but also sheds new light on potential therapeutic opportunities.

Most protein post-translational modifications are reversible and dynamically occur in a timely and spatially dependent manner. Abnormal post-translational protein modification events result in deregulated cell signaling, genome instability, and other aberrant biological processes, contributing to the development of human diseases, including cancers. Prior efforts in developing small-molecule inhibitors targeting aberrantly activated enzymes such as kinases show promise for cancer treatment. We hope this collection advances our understanding of the post-translational protein modification events driving disease and their regulatory mechanisms, in order to facilitate the identification of novel drug targets with potential for the development of novel therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)